Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Mylan reaches $30 million settlement in SEC’s EpiPen probe

Mylan NV reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to the company’s emergency allergy shot EpiPen, which became the center of a firestorm over price increases.

Read More »

Indivior launches generic version of own opioid drug

Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.

Read More »

Study Shows Drugs on FDA Shortage List Are Likely to See Price Hikes

According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.

Read More »

Mylan Chops Another 200 to 300 Jobs

Mylan reportedly let go between 200 and 300 people from its West Virginia operations.

Read More »

Mylan tweaks full-year forecasts on lift from Copaxone generic

Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.

Read More »

Cancer drug prices rising far faster than inflation

The prices of injectable cancer drugs – even older medicines around since the 1990s – are increasing at a rate far higher than inflation, researchers report in the Journal of Clinical Oncology.

Read More »

FDA moves to smooth path for complex generics

The U.S. FDA announced measures designed to speed to market generic versions of complex drugs in an effort to address the rising costs of pharmaceuticals.

Read More »

U.S. FDA warns of problems with EpiPen manufacturing plant

A U.S. regulator told Pfizer Inc.’s Meridian Medical Technologies division, maker of the EpiPen injector device, that serious component and product failures have been associated with patient deaths and severe illness.

Read More »

Mylan, U.S. finalize EpiPen settlement

Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.

Read More »

Mylan cuts forecasts on delays in new drugs

Mylan NV said that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability in 2017 and 2018.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom